Abacavir Sulfate Dolutegravir Sodium Lamivudine
| Evidence Level: L5 | Predicted Indications: 0 |
Table of Contents
- Abacavir Sulfate Dolutegravir Sodium Lamivudine
- ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE: No Predicted Indications (Insufficient Data)
ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE: No Predicted Indications (Insufficient Data)
One-Sentence Summary
Abacavir + Dolutegravir + Lamivudine is a three-in-one fixed-dose antiretroviral combination (brand name Triumeq), originally used for HIV-1 infection treatment. In this Evidence Pack, TxGNN has not generated any new indication predictions, and this combination drug currently has no approval record on the Taiwan market, resulting in lack of data foundation for most assessment fields. Before filling key data gaps (package insert warnings, MOA, prediction results), it is recommended to Hold further drug repurposing assessment.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV-1 infection (per international standard knowledge; this Pack does not provide Taiwan package insert data) |
| Predicted New Indication | None (TxGNN did not output any repurposing candidates in this run) |
| TxGNN Prediction Score | Not applicable |
| Evidence Level | Cannot be determined (no predictions, no clinical trials, no literature) |
| US Market Status | Not marketed (no approval record found in Taiwan drug database) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
The predicted_indications field in the current Evidence Pack is empty; the TxGNN model did not output any drug repurposing candidates for this combination drug, making mechanistic linkage analysis or indication appropriateness assessment not feasible.
Based on available background information, this combination consists of three fixed-ratio components:
- Abacavir (ABC): Nucleoside reverse transcriptase inhibitor (NRTI), requires metabolic activation to carbovir triphosphate before competitively inhibiting HIV-1 reverse transcriptase
- Dolutegravir (DTG): Integrase strand transfer inhibitor (INSTI), blocks HIV-1 DNA integration into the host genome
- Lamivudine (3TC): NRTI with concurrent HBV activity, inhibits both HBV and HIV-1 reverse transcriptase
The three components act on different targets in the HIV-1 replication cycle, exerting synergistic antiviral effects. Should TxGNN generate predictions for individual components in future runs (especially lamivudine’s HBV activity), HBV-related indication extension possibilities would merit priority evaluation.
Data Gap Summary
The current Evidence Pack contains the following two critical data gaps that must be filled before assessment can proceed:
| Gap ID | Gap Item | Severity | Impact | Remediation |
|---|---|---|---|---|
| DG001 | Taiwan package insert warnings / contraindications | Blocking | Cannot proceed to safety initial review | Download and parse the package insert PDF from FDA website |
| DG002 | Mechanism of Action (MOA) | High | Limits mechanistic-link analysis | Query the DrugBank API |
US Market Information
This drug has no approval record found in the Taiwan drug database, making it impossible to list authorization information.
Note: This three-in-one combination (Abacavir + Dolutegravir + Lamivudine) is approved in the United States under the brand name Triumeq (NDA 206708) for HIV-1 infection in adults and children ≥40 kg. If there is clinical need in Taiwan, reference may be made to US FDA approval information and the original package insert.
Safety Considerations
Safety data (warnings, contraindications, drug interactions) in this Evidence Pack are currently unavailable. Please consult the original package insert and US FDA-approved labeling (Triumeq Prescribing Information) for complete safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: TxGNN did not output any repurposing candidates, combined with no approval record on the Taiwan market and Blocking-level safety data gaps, the current baseline conditions for drug repurposing assessment are not present.
To proceed, the following is needed:
- Re-run TxGNN predictions: Confirm whether the model has established knowledge graph nodes for individual components (abacavir, dolutegravir, lamivudine) and separately generated prediction candidates
- Fill MOA data gap (DG002): Obtain DrugBank ID and complete mechanism description via DrugBank API as the foundation for mechanistic linkage analysis
- Fill safety data gap (DG001): Download and parse TFDA package insert PDF (if application has been filed) or substitute with US FDA-approved labeling to complete S1 safety initial review
- Confirm applicable assessment unit: Evaluate whether assessment should proceed on the combination drug as a whole or on individual components (especially lamivudine) as separate drug repurposing assessment subjects
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.